-+ 0.00%
-+ 0.00%
-+ 0.00%

Genprex says diabetes gene therapy reverses hyperglycemia in preclinical Type 2 models

PUBT·04/28/2026 11:04:47
Listen to the news
Genprex says diabetes gene therapy reverses hyperglycemia in preclinical Type 2 models
  • Genprex disclosed that collaborators will present new preclinical results for its GPX-002 (Pdx1/MafA) diabetes gene therapy at ASGCT 2026 on May 13.
  • Data to be presented show treatment reversed high blood sugar in Type 2 diabetic mouse models within four weeks.
  • Researchers also reported improved insulin-producing cell function and signs of more mature insulin production in treated animals.
  • Genprex highlighted a potential delivery path to humans using an endoscopic procedure to infuse therapy directly into pancreas.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA44329) on April 28, 2026, and is solely responsible for the information contained therein.